当前位置: 首页 >> 检索结果
321. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).
作者: Laetitia Dahan.;Frank Bonnetain.;Marc Ychou.;Emmanuel Mitry.;Mohamed Gasmi.;Jean-Luc Raoul.;Stéphane Cattan.;Jean-Marc Phelip.;Pascal Hammel.;Bruno Chauffert.;Pierre Michel.;Jean-Louis Legoux.;Philippe Rougier.;Laurent Bedenne.;Jean-François Seitz.; .
来源: Gut. 2010年59卷11期1527-34页
Gemcitabine is the standard chemotherapy for patients with metastatic pancreatic adenocarcinoma. Although the 5-fluorouracil (5FU), folinic acid and cisplatin combination (LV5FU2-CDDP) is an option, the optimal order of the regimens must be determined. The first strategic phase III trial comparing LV5FU2-CDDP followed by gemcitabine versus gemcitabine followed by LV5FU2-CDDP was conducted.
322. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis.
作者: William J Sandborn.;Jean Frederic Colombel.;Matthew Frankel.;Daan Hommes.;James N Lowder.;Lloyd Mayer.;Scott Plevy.;Pieter Stokkers.;Simon Travis.;Gert Van Assche.;Daniel C Baumgart.;Stephan R Targan.
来源: Gut. 2010年59卷11期1485-92页
Pilot studies with visilizumab, a humanised monoclonal antibody to CD3, suggest efficacy for corticosteroid-refractory ulcerative colitis (UC). A placebo-controlled trial was warranted.
323. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial.
作者: Marco Romano.;Antonio Cuomo.;Antonietta G Gravina.;Agnese Miranda.;Maria Rosaria Iovene.;Angelo Tiso.;Mariano Sica.;Alba Rocco.;Raffaele Salerno.;Riccardo Marmo.;Alessandro Federico.;Gerardo Nardone.
来源: Gut. 2010年59卷11期1465-70页
Antimicrobial drug resistance is a major cause of the failure of Helicobacter pylori eradication and is largely responsible for the decline in eradication rate. Quadruple therapy has been suggested as a first-line regimen in areas with clarithromycin resistance rate >15%. This randomised trial aimed at evaluating the efficacy of a levofloxacin-containing sequential regimen in the eradication of H pylori-infected patients in a geographical area with >15% prevalence of clarithromycin resistance versus a clarithromycin containing sequential therapy.
324. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study.
作者: Marjolijn Duijvestein.;Anne Christine W Vos.;Helene Roelofs.;Manon E Wildenberg.;Barbara B Wendrich.;Henricus W Verspaget.;Engelina M C Kooy-Winkelaar.;Frits Koning.;Jaap Jan Zwaginga.;Herma H Fidder.;Auke P Verhaar.;Willem E Fibbe.;Gijs R van den Brink.;Daniel W Hommes.
来源: Gut. 2010年59卷12期1662-9页
Mesenchymal stromal cells (MSCs) are pluripotent cells that have immunosuppressive effects both in vitro and in experimental colitis. Promising results of MSC therapy have been obtained in patients with severe graft versus host disease of the gut. Our objective was to determine the safety and feasibility of autologous bone marrow derived MSC therapy in patients with refractory Crohn's disease.
325. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C.
作者: Rami Moucari.;Nicole Forestier.;Dominique Larrey.;Dominique Guyader.;Patrice Couzigou.;Yves Benhamou.;Hélène Voitot.;Michel Vidaud.;Scott Seiwert.;Bill Bradford.;Stefan Zeuzem.;Patrick Marcellin.
来源: Gut. 2010年59卷12期1694-8页
Insulin resistance (IR) is a major predictor of treatment failure in patients with hepatitis C virus (HCV) infection treated with peginterferon/ribavirin. The aim of this study was to evaluate the short-term effect of an HCV protease inhibitor monotherapy on IR in parallel with an antiviral effect.
326. High detection rate of adenomas in familial colorectal cancer.
作者: A E van der Meulen-de Jong.;H Morreau.;M C J M Becx.;L F S J Crobach.;M van Haastert.;W R ten Hove.;J H Kleibeuker.;M A C Meijssen.;F M Nagengast.;M C M Rijk.;J M J I Salemans.;A Stronkhorst.;H A R E Tuynman.;J Vecht.;M L Verhulst.;W H de Vos tot Nederveen Cappel.;H Walinga.;O K Weinhardt.;B D Westerveld.;A M C Witte.;H J Wolters.;H F A Vasen.
来源: Gut. 2011年60卷1期73-6页
Subjects with one first-degree relative (FDR) with colorectal cancer (CRC) <50 years old or two FDRs with CRC have an increased risk for CRC (RR 4-6). Current guidelines recommend colonoscopic surveillance of such families. However, information about the yield of surveillance is limited. The aim of the present study was to evaluate the outcome of surveillance and to identify risk factors for the development of adenomas.
327. Association of the G-protein and α2-adrenergic receptor gene and plasma norepinephrine level with clonidine improvement of the effects of diuretics in patients with cirrhosis with refractory ascites: a randomised clinical trial.
作者: Y Y Yang.;H C Lin.;W P Lee.;C J Chu.;M W Lin.;F Y Lee.;M C Hou.;J S Jap.;S D Lee.
来源: Gut. 2010年59卷11期1545-53页
Clonidine is an α(2)-adrenoceptor agonist which, by coupling with G-protein, has been proposed as an alternative treatment for refractory ascites of patients with cirrhosis for several years. Genetic polymorphisms of β-adrenoceptor and angiotensin II type 1 receptor blockers have been reported to affect drug response in patients with cirrhosis. This study evaluated the clonidine-diuretic response rate, favourable predictors and genetic components of the clonidine-diuretic response in patients with cirrhosis with refractory ascites.
328. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.
作者: Robert J Fontana.;Jules L Dienstag.;Herbert L Bonkovsky.;Richard K Sterling.;Deepa Naishadham.;Zachary D Goodman.;Anna S F Lok.;Elizabeth C Wright.;Grace L Su.; .
来源: Gut. 2010年59卷10期1401-9页
The aim of this study was to explore the association of serum fibrosis marker levels with the risk of clinical and histological disease progression in a large cohort of patients with chronic hepatitis C (CHC).
329. Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy.
作者: Janine Rohrbach.;Nicola Robinson.;Gillian Harcourt.;Emma Hammond.;Silvana Gaudieri.;Meri Gorgievski.;Amalio Telenti.;Olivia Keiser.;Huldrych F Günthard.;Bernhard Hirschel.;Matthias Hoffmann.;Enos Bernasconi.;Manuel Battegay.;Hansjakob Furrer.;Paul Klenerman.;Andri Rauch.; .
来源: Gut. 2010年59卷9期1252-8页
Hepatitis C virus (HCV) infection is a major cause of morbidity in HIV infected individuals. Coinfection with HIV is associated with diminished HCV-specific immune responses and higher HCV RNA levels.
330. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome.
作者: Tamira K Klooker.;Breg Braak.;Karin E Koopman.;Olaf Welting.;Mira M Wouters.;Sicco van der Heide.;Michael Schemann.;Stephan C Bischoff.;Rene M van den Wijngaard.;Guy E Boeckxstaens.
来源: Gut. 2010年59卷9期1213-21页
Mast cell activation is thought to be involved in visceral hypersensitivity, one of the main characteristics of the irritable bowel syndrome (IBS). A study was therefore undertaken to investigate the effect of the mast cell stabiliser ketotifen on rectal sensitivity and symptoms in patients with IBS.
331. Analysis of deaths occurring within the Nottingham trial of faecal occult blood screening for colorectal cancer.
To report the causes of, and ages at, death of subjects in an English colorectal cancer screening trial.
332. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease.
作者: Iris Dotan.;Daniel Rachmilewitz.;Stefan Schreiber.;Rami Eliakim.;C Janneke van der Woude.;Asher Kornbluth.;Alan L Buchman.;Shimon Bar-Meir.;Bernd Bokemeyer.;Eran Goldin.;Christian Maaser.;Uma Mahadevan.;Ursula Seidler.;Jörg C Hoffman.;Douglas Homoky.;Terry Plasse.;Barbara Powers.;Paul Rutgeerts.;Daniel Hommes.; .
来源: Gut. 2010年59卷6期760-6页
Semapimod, a small molecule known to inhibit proinflammatory cytokine activity, was studied to determine the optimal dose necessary to achieve a response in patients with moderate to severe Crohn's disease (CD).
333. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial.
作者: Walter Reinisch.;Sieglinde Angelberger.;Wolfgang Petritsch.;Olga Shonova.;Milan Lukas.;Simon Bar-Meir.;Alexander Teml.;Elke Schaeffeler.;Matthias Schwab.;Karin Dilger.;Roland Greinwald.;Ralph Mueller.;Eduard F Stange.;Klaus R Herrlinger.; .
来源: Gut. 2010年59卷6期752-9页
The aim of the study was to compare azathioprine versus mesalazine tablets for the prevention of clinical recurrence in patients with postoperative Crohn's disease (CD) with moderate or severe endoscopic recurrence.
334. Endoscopic cyanoacrylate injection versus beta-blocker for secondary prophylaxis of gastric variceal bleed: a randomised controlled trial.
作者: Smruti Ranjan Mishra.;Barjesh Chander Sharma.;Ashish Kumar.;Shiv Kumar Sarin.
来源: Gut. 2010年59卷6期729-35页
Bleeding from gastric varices is often severe and difficult to manage. Endoscopic injection of gastric varices with cyanoacrylate is effective in prevention of rebleeding. The efficacy of beta-blockers in secondary prophylaxis of gastric variceal bleed has not been well studied. A comparison of the efficacy of beta-blocker treatment and cyanoacrylate injection for the prevention of gastric variceal rebleeding was carried out.
335. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study.
作者: John Dent.;Nimish Vakil.;Roger Jones.;Peter Bytzer.;Uwe Schöning.;Katarina Halling.;Ola Junghard.;Tore Lind.
来源: Gut. 2010年59卷6期714-21页
The aim of this study was to determine the accuracy of the diagnosis of gastro-oesophageal reflux disease (GORD) by the Reflux Disease Questionnaire (RDQ), family practitioners, gastroenterologists and a test of esomeprazole therapy.
336. Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention.
作者: Robert Benamouzig.;Bernard Uzzan.;Antoine Martin.;Jacques Deyra.;Julian Little.;Bernard Girard.;Stanislas Chaussade.; .
来源: Gut. 2010年59卷5期622-9页
Low-dose aspirin reduces the incidence of colorectal cancer and recurrence of adenomas. Cyclooxygenase-2 (COX-2), one of its main target enzymes, is reportedly over-expressed in colorectal adenomas.
337. Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design.
作者: Jyh-Ming Liou.;Jaw-Town Lin.;Chi-Yang Chang.;Mei-Jyh Chen.;Tsu-Yao Cheng.;Yi-Chia Lee.;Chien-Chuan Chen.;Wang-Huei Sheng.;Hsiu-Po Wang.;Ming-Shiang Wu.
来源: Gut. 2010年59卷5期572-8页
The efficacy of a levofloxacin-based regimen as the first-line treatment and a clarithromycin-based regimen as the second-line treatment for Helicobacter pylori infection remains unknown. The aim of this study was to assess the eradication rates of these two regimens using different administration sequences.
338. Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis.
作者: Nicholas J West.;Susan K Clark.;Robin K S Phillips.;John M Hutchinson.;Roger J Leicester.;Andrea Belluzzi.;Mark A Hull.
来源: Gut. 2010年59卷7期918-25页
The omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) has anticolorectal cancer activity in vitro and in preclinical models. The present study tested whether a novel, enteric-coated formulation of EPA, as the free fatty acid (EPA-FFA), has chemopreventative efficacy in patients with familial adenomatous polyposis (FAP), in a randomised, double-blind, placebo-controlled trial.
339. Sacral nerve stimulation for intractable constipation.
作者: Michael A Kamm.;Thomas C Dudding.;Jarno Melenhorst.;Michael Jarrett.;Zengri Wang.;Steen Buntzen.;Claes Johansson.;Søren Laurberg.;Harald Rosen.;Carolynne J Vaizey.;Klaus Matzel.;Cor Baeten.
来源: Gut. 2010年59卷3期333-40页
Traditional surgical procedures for intractable idiopathic constipation are associated with a variable outcome and substantial morbidity. The symptomatic response, physiological effect and effect on quality of life of sacral nerve stimulation (SNS) were evaluated in patients with constipation (slow transit and normal transit with impaired evacuation).
340. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial.
作者: A Straumann.;S Conus.;P Grzonka.;H Kita.;G Kephart.;C Bussmann.;C Beglinger.;D A Smith.;J Patel.;M Byrne.;H-U Simon.
来源: Gut. 2010年59卷1期21-30页
Eosinophilic oesophagitis (EoO) is a clinicopathological condition defined by proton pump inhibitor-refractory oesophageal symptoms combined with oesophageal eosinophilia. The pharmacodynamic effect of mepolizumab (a humanised anti-interleukin-5 monoclonal antibody) in EoO was evaluated.
|